LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --


 
 
            Fourth quarter                                                                                                    
 
 
            January-December




    Net sales reached SEK 18.3 (17.2) million
        
        
          The operating result totaled SEK -10.2 (-13.7) million.      Net sales reached SEK 53.9 (45.6) million.
     
        
          Earnings per share, basic and diluted, were SEK -0.05 (-0.05).
        
        
          Cash flow from      The operating result totaled SEK -51.4 (-52.1) million.
                       operating activities totaled SEK 0.5 (-20.6) million.                                                               
          Earnings per share, basic and diluted, were SEK -0.21 (-
                                                                                                                                                     0.28).
        
        
          Cash flow from operating activities
                                                                                                                                        for the period totaled SEK -41.0 (-60.5) million.
                                                                                                                                                Net cash totaled SEK 32.1 (73.0) million at year-end.

Comment from CEO Sana Alajmovic

"During my first weeks, I have placed great emphasis on gaining a thorough understanding of the business and forming a clear view of both our current position and future potential. I see an organization with deep expertise, strong commitment, and a shared ambition to take ColdZyme into its next phase of growth.

During the fourth quarter, sales continued to improve, with net sales totalling SEK 18.3 million (17.2). For the full year, net sales totalled SEK 53.9 million, corresponding to growth of 18.3 per cent compared with 2024", says Sana Alajmovic, CEO.

Significant events during the quarter

On October 13, Enzymatica announced the appointment of Holger Lembrér as the new CFO, effective no later than April 2026.

Significant events after the quarter

No significant events were reported after the end of the quarter.

Other events during and after the quarter

In October, ColdZyme Eucalyptus was launched as the latest flavor in the ColdZyme® range. The product offers the same clinically proven effect as the other flavors and was introduced to the Swedish market as a new option alongside menthol and strawberry.
Enzymatica strengthened its position in elite sport through three strategic partnerships - with the Swedish Biathlon Federation as Official Supplier ahead of Milan 2026 and with British GB Snowsport and the UK Sports Institute (UKSI), collectively strengthening ColdZyme's presence in high-performance sporting environments in Sweden and the United Kingdom.
On 1 February, Sana Alajmovic was appointed Chief Executive Officer of Enzymatica AB.
Following the appointment of the new CEO, the Board of Directors has initiated a review of Enzymatica's financial targets. Updated targets are intended to be presented in the latter part of 2026.

The full report is available at https://www.enzymatica.com/investors/financial-reports/

The information in this press release is such that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 18 February 2026 at 08:30 CET.

For more information, please contact:

Sana Alajmovic, CEO, Enzymatica AB
Phone: +46 723 89 33 96 | Email: sana.alajmovic@enzymatica.com

Enzymatica AB is headquartered in Lund and listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se.
Enzymatica's Certified Adviser is DNB Carnegie Investment Bank AB (publ).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/year-end-report-2025--new-ceo-takes-the-helm---initiates-the-next-phase-of-enzymatica-s-internationa,c4309089

The following files are available for download:


 
 https://mb.cision.com/Main/18091/4309089/3939547.pdf            The full report
                                                                     (PDF)



 
 https://mb.cision.com/Public/18091/4309089/9bb74a729601193e.pdf Press release
                                                                     (PDF)

View original content:https://www.prnewswire.co.uk/news-releases/year-end-report-2025-new-ceo-takes-the-helm--initiates-the-next-phase-of-enzymaticas-international-expansion-302691419.html

Tags

More Like This

Enzymatica AB Year-end report 2024: Strong performance in core markets - preparing for international growth

Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion

Quarterly report Q2/2025: Strong development in Sweden and increased international activity: Enzymatica AB

Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

Interim report Q2/2024: Enzymatica builds momentum for expansion

Year-end report 2023: Scientific and regulatory progress generating international interest

Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets

Enzymatica AB - Interim report Q3/2023: Research results that reshape the competitive landscape